The NTX assay in the follow-up of the osteoporotic patients: 3 years of alendronate treatment

摘要: Abstract These studies were conducted on 38 female patients treated with alendronate (10 mg/day, per os) for 3 years, because of osteoporosis. Of these patients, 29 in the menopausal age longer than 10 and remaining nine menopausa shorter years. Urine sample taken at start treatment every 6 months afterward crosslinked N-telopeptides type I collagen (NTx) have been measured them by means an ELISA technique. Bone mineral density (BMD) has recorded ultradistal (UDBMD) mediodistal (MDBMD) region radius non-dominant side. Body mass index (BMI) subjects also determined each time. The baseline values NTx varied very much, scattered a range 11–215 nanomoles bone equivalent/millimoles creatinine (nM BCE/mM Cr), average 59±46; those UDBMD MDBMD amounted to 258±63 587±112 mg/cm 2 , respectively. NTx, BMD does not correlate cach other. Both increased almost linearly total study pool during 3-years-long treatment, being 3.0–9.2 0.8–2.5% higher terms MDBMD, concentrations decreased same time 30–35%. It is concluded that monitoring urine levels may be useful antiosteoporotic treatments, reduction indicator slowing down turnover losses, as was observed therapy.